相关实验视频
Updated: Jul 4, 2025

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
6.7K
作为有前途的MAO-A向抗抑郁药物:更新
Diksha Choudhary1, Rajwinder Kaur1, Thakur Gurjeet Singh1
1Chitkara College of Pharmacy, Chitkara University, Punjab, 140401, India.
Current topics in medicinal chemistry
|February 6, 2024
概括
最近的研究强调了pyrazoline衍生物作为有前途的抗抑郁药. 这些化合物通过抑制单胺氧化酶A (MAO-A) 来治疗抑郁症,并提供新的治疗途径.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抑郁症是一个重要的全球健康问题,与神经递质失衡有关,并可能导致像自杀这样的严重结果.
- 含有的异环化合物,特别是pyrazoline衍生物,以其抗抑郁药物特性而闻名.
- 皮拉佐林支架表现出抑制单胺氧化酶 (MAO) 酶异型的选择性和亲和力,这在神经递质调节中至关重要.
研究的目的:
- 审查最近 (2019-2023) 含有pyrazoline的衍生物作为抑郁症治疗的潜在MAO-A抑制剂的进展.
- 为了提供这些pyrazoline衍生物的结构洞察力和结构-活性关系 (SAR) 分析.
- 探索基药物对抑郁症的结合相互作用和临床试验状态.
主要方法:
- 从2019年至2023年,文献综述侧重于pyrazoline衍生物及其MAO-A抑制活性.
- 对已识别的pyrazoline化合物进行结构-活性关系 (SAR) 的分析.
- 在基中进行分子对接研究,以调查与MAO-A酶活性部位的结合相互作用.
主要成果:
- 几种pyrazoline衍生物显示出对MAO-A酶的显著抑制.
- 在学研究显示,特定的pyrazoline结构和MAO-A活性部位之间存在强大的结合相互作用.
- 该审查整合了最近关于基于pyrazoline的MAO-A抑制剂的发现,包括它们的SAR和临床相关性.
结论:
- 罗衍生物代表了一类有希望的化合物,用于开发针对MAO-A的新型抗抑郁药.
- 需要进一步的化和临床研究来优化和验证这些基于的MAO-A抑制剂.
- 本综述为合理设计用于抑郁症管理的新治疗药物提供了宝贵的见解.
更多相关视频
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
234
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
234
Antidepressant Drugs: Overview
490
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
490
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
394
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
394
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K

